Microbial Influences on Immune Checkpoint Inhibitor Response in Melanoma: The Interplay between Skin and Gut Microbiota

被引:6
作者
Bouferraa, Youssef [1 ]
Fares, Callie [2 ]
Zerdan, Maroun Bou [3 ]
Kennedy, Lucy Boyce [4 ]
机构
[1] Cleveland Clin Fdn, Dept Internal Med, Cleveland, OH 44195 USA
[2] Amer Univ Beirut, Fac Med, Beirut 2020, Lebanon
[3] SUNY Upstate Med Univ, Dept Internal Med, New York, NY 13205 USA
[4] Cleveland Clin Fdn, Taussig Canc Inst, Dept Hematol & Med Oncol, Cleveland, OH 44195 USA
关键词
melanoma; immune checkpoint inhibitors; gut microbiota; skin microbiota; immune-related adverse events; ADVERSE EVENTS; CANCER; IMMUNOTHERAPY; MECHANISMS; THERAPY; TLR4;
D O I
10.3390/ijms24119702
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Immunotherapy has revolutionized the treatment of melanoma, but its limitations due to resistance and variable patient responses have become apparent. The microbiota, which refers to the complex ecosystem of microorganisms that inhabit the human body, has emerged as a promising area of research for its potential role in melanoma development and treatment response. Recent studies have highlighted the role of microbiota in influencing the immune system and its response to melanoma, as well as its influence on the development of immune-related adverse events associated with immunotherapy. In this article, we discuss the complex multifactorial mechanisms through which skin and gut microbiota can affect the development of melanoma including microbial metabolites, intra-tumor microbes, UV light, and the immune system. In addition, we will discuss the pre-clinical and clinical studies that have demonstrated the influence of different microbial profiles on response to immunotherapy. Additionally, we will explore the role of microbiota in the development of immune-mediated adverse events.
引用
收藏
页数:16
相关论文
共 65 条
  • [31] Li Y, 2019, NAT COMMUN, V10, DOI [10.1038/s41467-019-09525-y, 10.1038/s41467-019-12385-1]
  • [32] Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
    Liu, Wenhui
    Ma, Fang
    Sun, Bao
    Liu, Yiping
    Tang, Haoneng
    Luo, Jianquan
    Chen, Huiqing
    Luo, Zhiying
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [33] Faecalibacterium prausnitzii: from microbiology to diagnostics and prognostics
    Lopez-Siles, Mireia
    Duncan, Sylvia H.
    Jesus Garcia-Gil, L.
    Martinez-Medina, Margarita
    [J]. ISME JOURNAL, 2017, 11 (04) : 841 - 852
  • [34] Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies
    Lu, Yuting
    Yuan, Xiangliang
    Wang, Miao
    He, Zhihao
    Li, Hongzhong
    Wang, Ji
    Li, Qin
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2022, 15 (01)
  • [35] Preventive effect of Lactobacillus reuteri on melanoma
    Luo, Meng
    Hu, MiaoMiao
    Xu, Feng
    Wu, XiaoLi
    Dong, DeGang
    Wang, WanChun
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2020, 126
  • [36] Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
    Mager, Lukas F.
    Burkhard, Regula
    Pett, Nicola
    Cooke, Noah C. A.
    Brown, Kirsty
    Ramay, Hena
    Paik, Seungil
    Stagg, John
    Groves, Ryan A.
    Gallo, Marco
    Lewis, Ian A.
    Geuking, Markus B.
    McCoy, Kathy D.
    [J]. SCIENCE, 2020, 369 (6510) : 1481 - +
  • [37] The gut microbiome and melanoma: A review
    Makaranka, Stanislau
    Scutt, Freya
    Frixou, Mikaela
    Wensley, Katherine E.
    Sharma, Ravi
    Greenhowe, Jennifer
    [J]. EXPERIMENTAL DERMATOLOGY, 2022, 31 (09) : 1292 - 1301
  • [38] Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
    Martins, Filipe
    Sofiya, Latifyan
    Sykiotis, Gerasimos P.
    Lamine, Faiza
    Maillard, Michel
    Fraga, Montserrat
    Shabafrouz, Keyvan
    Ribi, Camillo
    Cairoli, Anne
    Guex-Crosier, Yan
    Kuntzer, Thierry
    Michielin, Olivier
    Peters, Solange
    Coukos, Georges
    Spertini, Francois
    Thompson, John A.
    Obeid, Michel
    [J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (09) : 563 - 580
  • [39] Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1
    McCulloch, John A.
    Davar, Diwakar
    Rodrigues, Richard R.
    Badger, Jonathan H.
    Fang, Jennifer R.
    Cole, Alicia M.
    Balaji, Ascharya K.
    Vetizou, Marie
    Prescott, Stephanie M.
    Fernandes, Miriam R.
    Costa, Raquel G. F.
    Yuan, Wuxing
    Salcedo, Rosalba
    Bahadiroglu, Erol
    Roy, Soumen
    DeBlasio, Richelle N.
    Morrison, Robert M.
    Chauvin, Joe-Marc
    Ding, Quanquan
    Zidi, Bochra
    Lowin, Ava
    Chakka, Saranya
    Gao, Wentao
    Pagliano, Ornella
    Ernst, Scarlett J.
    Rose, Amy
    Newman, Nolan K.
    Morgun, Andrey
    Zarour, Hassane M.
    Trinchieri, Giorgio
    Dzutsev, Amiran K.
    [J]. NATURE MEDICINE, 2022, 28 (03) : 545 - +
  • [40] Skin microbiome in acral melanom Corynebacterium is associated with advanced melanoma
    Mizuhashi, Satoru
    Kajihara, Ikko
    Sawamura, Soichiro
    Kanemaru, Hisashi
    Makino, Katsunari
    Aoi, Jun
    Makino, Takamitsu
    Masuguchi, Shinichi
    Fukushima, Satoshi
    Ihn, Hironobu
    [J]. JOURNAL OF DERMATOLOGY, 2021, 48 (01) : E15 - E16